(2S,3S,4R,5R)-2-(3-Ethyl-isoxazol-5-yl)-5-[6-(1-ethyl-propylamino)-2-(2-piperidin-1-yl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol | 235744-12-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,4R,5R)-2-(3-Ethyl-isoxazol-5-yl)-5-[6-(1-ethyl-propylamino)-2-(2-piperidin-1-yl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol
• 英文别名: (2S,3S,4R,5R)-2-(3-ethyl-1,2-oxazol-5-yl)-5-[6-(pentan-3-ylamino)-2-(2-piperidin-1-ylethylamino)purin-9-yl]oxolane-3,4-diol
• CAS: 235744-12-4
• 化学式: C₂₆H₄₀N₈O₄
• 分子量: 528.655
• InChiKey: WSZKIEGTRVUDQA-IYXIZZNPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  147
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1051425B1

  公开（公告）日：2002-10-30
• US6762170B1
  申请人：——

  公开号：US6762170B1

  公开（公告）日：2004-07-13
• [EN] 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES<br/>[FR] DERIVES DE 2-(PURINE-9-YL)-TETRAHYDROFURANE-3,4-DIOL
  申请人：——

  公开号：WO1999038877A2

  公开（公告）日：1999-08-05

  [EN] There are provided according to the invention, novel compounds of formula (I) wherein R<1>, R<2> and R<3> are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
  [FR] L'invention concerne de nouveaux composés, représentés par la formule (I): dans laquelle R<1>, R<2> et R<3> sont tels que définis dans la description. L'invention concerne également des procédés permettant de préparer ces composés, des formulations les renfermant et leur utilisation pour le traitement thérapeutique des maladies inflammatoires.
• [EN] METHOD OF DETERMINING SUSCEPTIBILITY TO DISEASES<br/>[FR] METHODE PERMETTANT DE DETERMINER LA RECEPTIVITE A CERTAINES MALADIES
  申请人：GLAXO GROUP LTD

  公开号：WO2002036816A2

  公开（公告）日：2002-05-10

  The present invention relates to polymorphisms in the adenosine 2a (A2a) human receptor gene, and to the use of such polymorphisms in the prognosis, diagnosis and treatment of diseases associated with said receptor eg. asthma, chronic obstructive pulmonary disease (COPD), motor dyskinesia disorders (such as Parkinson's disease) or diseases associated with dysregulation of the immune system.
• [EN] NEW METHOD OF BRONCHODILATORY THERAPY<br/>[FR] NOUVELLE METHODE DE TRAITEMENT BRONCHODILATATEUR
  申请人：GLAXO GROUP LTD

  公开号：WO2002067909A1

  公开（公告）日：2002-09-06

  As a first aspect of the invention we provide a method of inducing bronchodilation in a human patient which comprises administering to that patient an effective amount of a selective A2a receptor agonist.